BIO-TECHNE CORP

Bio‑Techne’s slight dip hides a deeper slump—under‑priced, low volume, and lagging behind peers, signaling a need for a breakthrough to restore investor confidence.

Bio‑techne’s share edged up 0.08 % to $72.62, matching its 200‑day trend. Compare the modest gain to peers like Ionq and Manhattan in the biotech sector.

Bio‑Techne shares dip slightly to $72.58, trading near a 52‑week high while maintaining a $11.4B market cap—key data for investors tracking biotech stock trends.